My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidlines Journals & Publications Policy & Advocacy Meetings About IDSA
July 2008
Volume 18, Number 7
Zoster Vaccine Recommended for All Persons Over 60

Zoster vaccine is now recommended for all persons aged over 60 years who have no contraindications, including patients who have had a previous episode of zoster or who have chronic medical conditions. According to the Advisory Committee on Immunization Practices (ACIP), patients do not need to be asked about their history of varicella or to have serologic testing prior to administering the vaccine. ACIP’s recommendations were published in the June 6 issue of Morbidity and Mortality Weekly Report (MMWR June 6, 2008/57(05);1-30).
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


New Encephalits Guidelines Published
HIV Opportunistic Infections Guidelines Updated
IDSA Journal Club, July 2008
In the IDSA Journals
ACIP Makes New Recommendations on Rabies, HPV, Pneumococcal Vaccines
CDC Updates Recommendations on Prevention, Control of Influenza
Zoster Vaccine Recommended for All Persons Over 60
EIN: MAI Disease and Clofazimine
Drug Approvals, Recalls, Adverse Events Update
Congress Stops Steep Medicare Physician Payment Cuts, For Now
CMS to Launch New Website to Compare Physicians
U.S. Global AIDS Program Expands
Federal ID Budgets Likely to See Small Increases
IDSA Advocacy Update: IDSA Opposes Federal Antiviral, Antibiotic Stockpiling Plans
IDSA/SHEA Infection Control Fellows Course Available Online
Looking For CME Opportunities?
Congratulations, New IDSA Fellows!
IDSA 2008 Elections Coming Up
Members on the Move
Welcome, New IDSA Members!
View archived IDSA News issues
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'idsa@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.